Market Overview

Aimmune Therapeutics Announces CEO Jayson Dallas Will Present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 15th

Share:

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Jayson Dallas, M.D., will give his first public
presentation as the company's President and CEO at the 2018 Wedbush
PacGrow Healthcare Conference in New York on Wednesday, August 15 at
1:55 p.m. Eastern Time.

As Aimmune prepares to submit regulatory filings for marketing approval
of AR101 in the United States and Europe, Dr. Dallas will provide a
corporate overview and outline his vision for delivering on Aimmune's
commitment to serving those affected by food allergies. AR101 is
Aimmune's investigational biologic oral immunotherapy for
desensitization of patients with peanut allergy.

Event: Wedbush PacGrow Healthcare Conference
Presentation
Date:
August 15, 2018
Presentation Time: 1:55 p.m.
Eastern Time
Presenter: Jayson Dallas, M.D., President &
CEO, Aimmune Therapeutics

A live webcast of the presentation will be accessible on the Events page
under the Investor Relations section of the Aimmune Therapeutics website
at www.aimmune.com.
A replay of the webcast will be available for at least 30 days.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
treatments for life-threatening food allergies. The company's
Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is
intended to provide meaningful levels of protection against allergic
reactions resulting from accidental exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune's first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA's Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age. Aimmune plans to submit regulatory filings for
marketing approval of AR101 in the United States and Europe based on
data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in
4-17 year-old subjects met all its primary and secondary endpoints, and
additional ongoing and completed AR101 clinical trials. For more
information, please see www.aimmune.com.

This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.

Forward-Looking Statements

Statements contained in this press release regarding matters that are
not historical facts are "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding: Aimmune's expectations regarding its new chief
executive officer; Aimmune's expectations regarding the potential
benefits of AR101; Aimmune's expectations regarding potential
applications of the CODIT™ approach to treating life-threatening food
allergies; and Aimmune's expectations regarding the timing of potential
regulatory filings for marketing approval of AR101 in the United States
and Europe. Risks and uncertainties that contribute to the uncertain
nature of the forward-looking statements include: the expectation that
Aimmune will need additional funds to finance its operations; the
company's ability to initiate and/or complete clinical trials; the
unpredictability of the regulatory process; the possibility that the
results of early clinical trials may not be predictive of future
results; the possibility that Aimmune's clinical trials will not be
successful; Aimmune's dependence on the success of AR101; the company's
reliance on third parties for the manufacture of the company's product
candidates; possible regulatory developments in the United States and
foreign countries; and Aimmune's ability to attract and retain senior
management personnel. These and other risks and uncertainties are
described more fully in Aimmune's most recent filings with the
Securities and Exchange Commission, including its Quarterly Report on
Form 10-Q for the quarter ended March 31, 2018. All forward-looking
statements contained in this press release speak only as of the date on
which they were made. Aimmune undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.

View Comments and Join the Discussion!